RCAR - RenovaCare, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
1.3700
+0.0400 (+3.01%)
At close: 3:42PM EDT
Stock chart is not supported by your current browser
Previous Close1.3300
Open1.3400
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.3400 - 1.3700
52 Week Range0.9500 - 3.5200
Volume3,875
Avg. Volume13,553
Market Cap119.43M
Beta (3Y Monthly)3.49
PE Ratio (TTM)N/A
EPS (TTM)-0.0250
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Former Johnson & Johnson Worldwide Director for Advanced Wound Care Joins RenovaCare
    GlobeNewswire5 days ago

    Former Johnson & Johnson Worldwide Director for Advanced Wound Care Joins RenovaCare

    Dr. Walthall joins RenovaCare within weeks of the appointments of Dr. Rodney L. Sparks as Vice President of Intellectual Property and Dr. Roger Esteban-Vives to the position of Vice President of Research and Product Development. Among other duties, Dr. Walthall will provide ongoing support to Dr. Esteban-Vives in new product development and expanding the use of the RenovaCare technology platform for medical conditions beyond burns, such as reconstructive surgery and cosmetic applications, including acne scarring, wrinkles and tattoo removal.

  • RenovaCare Appoints VP to Expand and Accelerate Intellectual Property and Licensing
    GlobeNewswire19 days ago

    RenovaCare Appoints VP to Expand and Accelerate Intellectual Property and Licensing

    “Just over six months ago, I made an equity investment of $15.5 million in RenovaCare to pursue human clinical trials for the SkinGun™ and explore the use of our cell spray technology for medical conditions beyond burns,” stated Mr. Harmel S. Rayat, the Company’s Chairman. Dr. Rodney Sparks is a respected intellectual property lawyer and technology licensing expert with decades of experience.  He’s also a regarded scientist with postdoctoral training from the Johns Hopkins University and a research fellowship from the Mayo Clinic.

  • UPDATE -- Vice President to Expand RenovaCare SkinGun™ Technology for New Medical Conditions Beyond Burns
    GlobeNewswirelast month

    UPDATE -- Vice President to Expand RenovaCare SkinGun™ Technology for New Medical Conditions Beyond Burns

    RenovaCare, Inc., (Symbol: RCAR; www.renovacareinc.com) developer of patented technologies for spraying a patient’s own stem cells onto burns and wounds for accelerated self-healing, is pleased to announce the appointment of Dr. Roger Esteban-Vives as Vice President of Research and Product Development. The appointment of Dr. Esteban-Vives follows a November 2018 equity financing of $15.5 million by Kalen Capital Corporation, wholly owned by Mr. Harmel S. Rayat, the Company’s Chairman.

  • RenovaCare Chairman Invests $15.5 Million to Fund SkinGun™ Regulatory Submissions and Clinical Trials
    Business Wire8 months ago

    RenovaCare Chairman Invests $15.5 Million to Fund SkinGun™ Regulatory Submissions and Clinical Trials

    “I’m more confident than ever in our mission to replace painful and costly skin grafting surgeries with an ultra-gentle healing mist of one’s own skin cells. At this time, the company will not post information on social media that could be deemed to be material information unless that information was distributed to public distribution channels first.